血管内皮细胞生长因子受体Flt-1结合小肽的融合表达及活性鉴定

血管内皮细胞生长因子 (VEGF)通过结合其酪氨酸激酶受体KDR、fms样酪氨酸激酶 1(Flt 1)调节新生血管形成 ;筛选能封闭VEGF结合Flt 1的小肽 ,可以通过阻断肿瘤血管形成 ,抑制实体瘤生长 .将从噬菌体 12肽库中筛选获得的 2个能与Flt 1结合的阳性噬菌体克隆 (F5 6和F90 )十二肽DNA(36bp)克隆到表达载体pQE4 2中 ,在大肠杆菌M15中稳定表达二氢叶酸还原酶融合蛋白(DHFR F5 6 F90 ) ,经变性、复性后得到纯度达 90 %的可溶性蛋白 .ELISA检测表明 ,DHFR F5 6 F90能结合可溶性受体sFlt 1和血管内皮细胞 ;12 5I VEGF竞争抑制实验显示 ,DHFR F5 6能竞争抑制VEGF同可溶性受体sFlt 1结合 .结果提示 ,F5 6可能是VEGF受体Flt 1的有效拮抗剂 ,具有抗肿瘤新生血管形成的潜在应用前景     

Cloning and Expression of EGFR Tyrosine Kinase and Construction of the Screening Model for the Enzymatic Inhibitors

表皮生长因子受体(Epidermal growth factor receptor,EGFR)属受体酪氨酸激酶(Tyrosine kinase,TK)家族,其胞内的酪氨酸激酶在细胞信号转导通路中具有十分重要的作用。许多肿瘤的发生、发展都与EGFR胞内酪氨酸激酶的异常表达密切相关。因此,EGFR胞内酪氨酸激酶的抑制剂有可能成为治疗肿瘤的有效药物。本研究从人脐静脉内皮细胞(HUVEC) 提取总RNA,采用RT-PCR获得EGFR酪氨酸激酶催化域的编码基因。将其克隆至载体pET-30a,在E.coli BL21(DE3)中进行了成功表达,采用Ni-NTA亲和层析对其进行了纯化。通过对酶的活性的测定,证明重组EGFR酪氨酸激酶蛋白具有利用ATP催化底物发生磷酸化反应的激酶活性。以该重组激酶为靶位构建了酶抑制剂筛选模型,拟对微生物代谢产物进行筛选。     

人FGFR1的BacMam系统构建、表达、纯化与鉴定

目前激酶类蛋白的表达大多由昆虫细胞表达系统实现,采用BacMam系统来表达受体型酪氨酸激酶人FGFR1,旨在获得更接近天然结构与功能的重组蛋白.首先,将pDEST20载体的多角体蛋白启动子替换成CMV enhancer启动子,获得BacMam表达载体pDEST20-CMVe.通过Gateway系统,将FGFR1具有酪氨酸激酶活性的区域克隆至改造后的载体中.利用昆虫细胞Sf9产生病毒,P2代病毒转导哺乳动物细胞FreeStyle 293-F进行表达,经亲和纯化后,成功获得了75 kD的融合蛋白.通过磷酸化底物的反应检测此FGFR1激酶的活性.结果表明,BacMam系统是一个良好的表达重组激酶FGFR1的平台,并且所表达的激酶活性高于昆虫细胞表达的激酶蛋白.     

KDR酪氨酸激酶的克隆表达及纯化

VEGF作为一种血管内皮细胞有丝分裂原,通过与内皮细胞表面特定受体结合,从而导致新生血管的形成,其中VEGFR-2(KDR/FIk-1)在肿瘤血管形成中起重要作用,因此其抑制剂有可能发展成为治疗肿瘤的新药.采用大肠杆菌成功表达了具有酪氨酸激酶活性的KDR酪氨酸激酶催化域(KDR-CD).采用RT-PCR从人脐静脉内皮细胞中提取总RNA,获得KDR-CD的编码基因,将其克隆至pET-30a载体,在E. coli BL21(DE3)中进行了成功表达,采用Ni-NTA亲和层析对其进行了纯化,Western blotting结果显示表迭的KDR-CD蛋白自身磷酸化,重组KDR-CD蛋白具有利用ATP催化底物发生磷酸化反应的激酶活性.     

血管抑制素功能结构域K1与PKA底物磷酸化基序的融合表达及磷酸化标记

通过 RT- PCR,从人肝组织中扩增出血管形成抑制素 ( angiostatin) c DNA的 K1片段 ,经DNA序列分析证实其正确性 ;将 K1与 GST融合并带上 1 7个氨基酸的 PKA底物磷酸化基序 ,IPTG诱导表达 ,以还原型谷胱甘肽偶联的琼脂糖凝胶亲合层析直接从细菌裂解上清中纯化融合蛋白 ;以 PKA催化单位将 3 2 P通过磷酸化作用标记至纯化的蛋白 ,再用凝血酶切去 GST,进行SDS- PAGE.放射自显影结果显示 ,GSTag- K1和 Tag- K1分别在 40 k D和 1 7k D处有信号强而特异的显影条带 ,表明带有磷酸化序列的蛋白能够被 PKA特异地磷酸化标记     

表皮生长因子受体酪氨酸激酶的克隆表达和酶抑制剂筛选模型的构建

表皮生长因子受体（epidermal growth factor receptor,EGFR）属受体酪氨酸激酶（tyrosine kinase,TK）家族,其胞内的酪氨酸激酶在细胞信号转导通路中具有十分重要的作用。许多肿瘤的发生、发展都与EGFR胞内酪氨酸激酶的异常表达密切相关。因此,EGFR胞内酪氨酸激酶的抑制剂有可能成为治疗肿瘤的有效药物。从人脐静脉内皮细胞（HUVEC）提取总RNA,采用RT-PCR获得EGFR酪氨酸激酶催化域的编码基因。将其克隆至载体pET-30a,在E．coliBL21（DE3）中进行了成功表达,采用Ni-NTA亲和层析对其进行了纯化。通过对酶的活性的测定,证明重组EGFR酪氨酸激酶蛋白具有利用ATP催化底物发生磷酸化反应的激酶活性。以该重组激酶为靶位构建了酶抑制剂筛选模型,拟对微生物代谢产物进行筛选。     

Akt1原核表达载体GST-Akt1的构建及鉴定

目的:构建带GST标签的Akt1原核表达载体,获得GST-Akt1原核表达蛋白,并进行体外激酶实验验证其能否发生磷酸化修饰。方法:以乳腺文库为模板,采用PCR技术扩增出Akt1编码序列,将其插入p GEX-KG载体,鉴定正确后转化大肠杆菌Rossate诱导表达,纯化蛋白后进行体外激酶实验,检测得到的蛋白是否可以发生磷酸化修饰。结果:双酶切和测序结果表明GST-Akt1原核表达质粒构建成功,考马斯亮蓝染色结果表明GST-Akt1蛋白获得表达,体外激酶实验表明GST-Akt1蛋白可发生磷酸化修饰。结论:构建了带GST标签的Akt1原核表达载体,为进一步研究Akt1磷酸化发生和调节的机制奠定了基础。     

神经元突触内的非受体型酪氨酸激酶底物（英文）

非受体型酪氨酸激酶(non-receptor tyrosine kinase,nRTK)是一个较大的激酶家族,其功能是催化蛋白的酪氨酸磷酸化。nRTK家族中的几种常见亚型,比如Src和Fyn,可以在神经系统内表达。近年来的研究表明,神经元的突触部位含有多个nRTK的底物蛋白,这些底物蛋白主要包括谷氨酸受体(离子型和代谢型谷氨酸受体)、突触后构架蛋白、突触前调节蛋白和突触富含的多种蛋白激酶。在基础或刺激的状态下,nRTK可催化这些底物蛋白内特定酪氨酸的磷酸化,从而调节这些底物蛋白的多种生理、生化和生物物理功能。因为突触内的nRTK对突触变化信号非常敏感,所以突触nRTK被认为参与了突触传导活动的强度和效率等方面的调节。     

受体型酪氨酸激酶PDGFRβ在毕赤酵母中的表达与纯化

构建了受体酪氨酸激酶 PDGFRβ 的融合表达载体 pPIC3.5K-PDGFRβ, 转化毕赤酵母GS115, 通过组氨酸营养缺陷型筛选, G4l8 高拷贝菌株筛选, 以及摇瓶诱导表达筛选, 得到一株高表达 PDGFRβ 毕赤酵母菌株 M3。对该菌株进行5 L罐培养, 镍柱亲和纯化在 250 mmol/L 咪唑浓度下洗下 PDGFRβ 融合蛋白, Western blot验证约为90.08 kD, 酶联免疫反应检测表明融合表达的PDGFRβ 具有高的酪氨酸激酶活性。为筛选其小分子抑制剂奠定了基础。     

三羟异黄酮对豚鼠心室肌细胞内游离钙浓度的影响

用激光共聚焦显微镜观察研究三羟异黄酮(genistein,GST)对豚鼠心室肌细胞内游离钙浓度([Ca^2 ]i)的影响。结果用相对荧光强度(FI-F0／FX0,％)表示。实验结果显示,在正常台氏液、无钙台氏液和正常台氏液中加入3mmol／L EGTA后,GST(10～40μmol／L)浓度依赖性地降低细胞内钙浓度。蛋白酪氨酸磷酸酶抑制剂正钒酸钠(sodium orthovanadate)和L-型Ca^2 通道激动剂Bay K8644可部分抑制正常台氏液时GST的效应。当细胞外液钙浓度由1mmol／L增加到10mmol／L而诱发心室肌细胞钙超载时,部分心室肌细胞产生可传播的钙波,GST(40μmol／L)可降低钙波的传播速度和持续时间,最终阻断钙波。以上结果提示,GST降低心室肌细胞内游离钙浓度,此作用与其抑制电压依赖性Ca^2 通道、减弱酪氨酸激酶抑制和豚鼠心室肌细胞肌浆网内钙释放有关。     

Activation of the EGF receptor tyrosine kinase by divalent metal ions: comparison of holoreceptor and isolated kinase domain properties

The activation of the epidermal growth factor (EGF) receptor tyrosine kinase activity is thought to represent a key initial step in EGF-mediated mitogenesis. The mechanisms underlying the regulation of the EGF receptor tyrosine kinase activity were examined through comparisons of the holoreceptor, purified from human placenta, and a soluble 42 kDa tyrosine kinase domain (TKD), generated by the limited trypsin proteolysis of the holoreceptor. The results of these studies highlight the importance of divalent metal ions (Me2+), i.e., Mn2+ and Mg2+, as activators of the tyrosine kinase activity. Manganese is an extremely effective activator of the holoreceptor tyrosine kinase, and under some conditions (low ionic strength) it completely alleviates the need for EGF to stimulate activity. In contrast, Mg2+ only weakly stimulates the holoreceptor tyrosine kinase activity in the absence of EGF, but promotes essentially full activity in the presence of the growth factor. Like the holoreceptor, the soluble TKD is highly active in the presence of Mn2+. However, the isolated TKD is completely inactive in the presence of Mg2+, and, in fact, Mg2+ inhibits the Mn2(+)-stimulated tyrosine kinase activity. The differences in the effects of Mn2+ and Mg2+ on the isolated TKD were further demonstrated by monitoring the effects of Me2+ on the modification of a reactive cysteine residue(s) on the TKD. While Mn2+ potentiates the inhibition by cysteine-directed reagents of the tyrosine kinase activity, Mg2+ has no effect on either the rate or the extent of the inhibition. Both the regulation by Mn2+ of the kinase activity of the TKD and the potentiation by Mn2+ of the cysteine reactivity of the TKD occur over a millimolar concentration range, which implicates a direct binding interaction by the metal ion. Overall, these results demonstrate that there are two key activator sites on the EGF receptor, i.e., the EGF binding site on the extracellular domain and a Me2+ binding site on the cytoplasmic TKD. Me2+ interactions with the cytoplasmic kinase domain apparently result in conformational changes which regulate the levels of tyrosine kinase activity, influence the degree to which this activity is responsive to EGF, and probably account for the effects of Me2+ on the aggregation state of the receptor (Carraway, K.L., III, Koland, J.G. and Cerione, R.A. (1989) J. Biol. Chem. 264, 8699-8707). In general, Mg2(+)-induced conformation changes prime the receptor for activation by EGF, while Mn2+ can fully activate the receptor tyrosine kinase and thereby short-circuit growth factor control.     

可溶性VEGF受体Flt-1的基因克隆及其活性产物在原核中的表达

可溶性血管内皮细胞生长因子受体 ( Flt- 1 )具有受体拮抗剂作用 ,可竞争结合血管内皮细胞生长因子 ,( VEGF)并与其膜表面受体 Flt- 1及 KDR形成异源二聚体 ,最终阻断 VEGF的生物学活性 .利用 RT- PCR技术从人脐静脉内皮细胞扩增出 Flt- 1胞外 ～ 区 c DNA片段 ,通过基因重组将该片段克隆于谷胱甘肽转移酶 ( GST)融合蛋白表达载体 PGEX2 -T中 ,连接产物转化大肠杆菌XL1 - blue,经 IPTG诱导可获大量稳定表达的 Flt- 1 - GST融合蛋白 .该表达产物经变性复性处理后 ,可特异性结合 12 5 - VEGF.大量具有活性的可溶性 Flt- 1的获得有助于新的抗肿瘤血管形成方法的探索 .     

N-Terminal Cleavage and Release of the Ectodomain of Flt1 Is Mediated via ADAM10 and ADAM 17 and Regulated by VEGFR2 and the Flt1 Intracellular Domain

Flt is one of the cell surface VEGF receptors which can be cleaved to release an N-terminal extracellular fragment which, like alternately transcribed soluble Flt1 (sFlt1), can antagonize the effects of VEGF. In HUVEC and in HEK293 cells where Flt1 was expressed, metalloprotease inhibitors reduced Flt1 N-terminal cleavage. Overexpression of ADAM10 and ADAM17 increased cleavage while knockdown of ADAM10 and ADAM17 reduced N-terminal cleavage suggesting that these metalloproteases were responsible for Flt1 cleavage. Protein kinase C (PKC) activation increased the abundance and the cleavage of Flt1 but this did not require any residues within the intracellular portion of Flt1. ALLN, a proteasomal inhibitor, increased the abundance of Flt1 which was additive to the effect of PKC. Removal of the entire cytosolic region of Flt1 appeared to stimulate cleavage of Flt1 and Flt1 was no longer sensitive to ALLN suggesting that the cytosolic region contained a degradation domain. Knock down of c-CBL, a ring finger ubiquitin ligase, in HEK293 cells increased the expression of Flt1 although it did not appear to require a previously published tyrosine residue (1333Y) in the C-terminus of Flt1. Increasing VEGFR2 expression increased VEGF-stimulated sFlt1 expression and progressively reduced the cleavage of Flt1 with Flt1 staying bound to VEGFR2 as a heterodimer. Our results imply that secreted sFlt1 and cleaved Flt1 will tend to have local effects as a VEGF antagonist when released from cells expressing VEGFR2 and more distant effects when released from cells lacking VEGFR2.     

猪脾脏酪氨酸蛋白激酶的研究

 采用DEAE-Sepharose CL-6B离子交换层析和Tyrosine-agarose亲和层析,首次从猪脾脏30000Xg颗粒中部分纯化了酪氨酸蛋白激酶,其比活性约为12000pmol.min~(-1).mg~(-1)。磷酸氨基酸分析表明,该酶能催化合成多肽poly(Glu.Ala.Tyr)_n(6:3:1)中的酪氨酸(Tyr)磷酸化,对该多肤废物和ATP的Km值分别约为2mg/mL和15μmol/L。Mn~(2+)对部分纯化的酪氨酸蛋白激酶的最大激活活性高于Mg~(2+),其AC_(50)分别约为1.4mmol/L和8mmol/L;发现红花素能强烈地抑制该酶活性,其IC_(50)约为125μmol/L。     

人源蛋白酪氨酸磷酸酶SHP-2基因克隆与原核表达

目的:构建蛋白酪氨酸磷酸酶SHP-2的原核表达载体并在大肠杆菌中表达。方法:以人脑组织mRNA为模板,通过RT-PCR扩增出目标cDNA,构建蛋白酪氨酸磷酸酶SHP-2-pEASY-E1重组质粒。将重组质粒转化进E.coli TOP10感受态细胞中,通过菌落PCR和测序进行阳性克隆的筛选和验证,将正确的质粒转化E.coli Transetta感受态细胞中,通过SDS-PAGE和western-blot进行蛋白检测和验证,酶促动力学分析SHP-2可溶性蛋白的活性。结果:成功克隆SHP-2功能域,构建SHP-2-pEASY-E1原核表达载体,完成可溶性蛋白的表达;酶促动力学分析结果为:米氏常数Km=0.97mmol/L,Vmax为13.57mmol/L/s。结论:本研究成功构建SHP-2的原核表达载体,重组表达的SHP-2蛋白具有较高的磷酸酶活性。     

RACK1 regulates VEGF/Flt1-mediated cell migration via activation of a PI3K/Akt pathway

Vascular endothelial growth factor (VEGF) is vital to physiological as well as pathological angiogenesis, and regulates a variety of cellular functions, largely by activating its 2 receptors, fms-like tyrosine kinase (Flt1) and kinase domain receptor (KDR). KDR plays a critical role in the proliferation of endothelial cells by controlling VEGF-induced phospholipase Cγ-protein kinase C (PLCγ-PKC) signaling. The function of Flt1, however, remains to be clarified. Recent evidence has indicated that Flt1 regulates the VEGF-triggered migration of endothelial cells and macrophages. Here, we show that RACK1, a ubiquitously expressed scaffolding protein, functions as an important regulator of this process. We found that RACK1 (receptor for activated protein kinase C 1) binds to Flt1 in vitro. When the endogenous expression of RACK1 was attenuated by RNA interference, the VEGF-driven migration was remarkably suppressed whereas the proliferation was unaffected in a stable Flt1-expressing cell line, AG1-G1-Flt1. Further, we demonstrated that the VEGF/Flt-mediated migration of AG1-G1-Flt1 cells occurred mainly via the activation of the PI3 kinase (PI3K)/Akt and Rac1 pathways, and that RACK1 plays a crucial regulatory role in promoting PI3K/Akt-Rac1 activation.     

Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1

Therapeutic angiogenesis is likely to require the administration of factors that complement each other. Activation of the receptor tyrosine kinase (RTK) Flk1 by vascular endothelial growth factor (VEGF) is crucial, but molecular interactions of other factors with VEGF and Flk1 have been studied to a limited extent. Here we report that placental growth factor (PGF, also known as PlGF) regulates inter- and intramolecular cross talk between the VEGF RTKs Flt1 and Flk1. Activation of Flt1 by PGF resulted in intermolecular transphosphorylation of Flk1, thereby amplifying VEGF-driven angiogenesis through Flk1. Even though VEGF and PGF both bind Flt1, PGF uniquely stimulated the phosphorylation of specific Flt1 tyrosine residues and the expression of distinct downstream target genes. Furthermore, the VEGF/PGF heterodimer activated intramolecular VEGF receptor cross talk through formation of Flk1/Flt1 heterodimers. The inter- and intramolecular VEGF receptor cross talk is likely to have therapeutic implications, as treatment with VEGF/PGF heterodimer or a combination of VEGF plus PGF increased ischemic myocardial angiogenesis in a mouse model that was refractory to VEGF alone.     

Flt3 ligand structure and unexpected commonalities of helical bundles and cystine knots

Human Flt3 ligand (Flt3L) stimulates early hematopoiesis by activating a type III tyrosine kinase receptor on primitive bone marrow stem cells. The crystal structure of soluble Flt3L reveals that it is a homodimer of two short chain alpha-helical bundles. Comparisons of structure-function relationships of Flt3L with the homologous hematopoietic cytokines macrophage colony stimulating factor (MCSF) and stem cell factor (SCF) suggest that they have a common receptor binding mode that is distinct from the paradigm derived from the complex of growth hormone with its receptor. Furthermore, we identify recognition features common to all helical and cystine-knot protein ligands that activate type III tyrosine kinase receptors, and the closely related type V tyrosine kinase receptors.     

Role of threonines in the Arabidopsis thaliana somatic embryogenesis receptor kinase 1 activation loop in phosphorylation

The Arabidopsis thaliana somatic embryogenesis receptor kinase 1 (AtSERK1) gene encodes a receptor-like protein kinase that is transiently expressed during embryogenesis. To determine the intrinsic biochemical properties of the AtSERK1 protein, we have expressed the intracellular catalytic domain as a glutathione S-transferase fusion protein in Escherichia coli. The AtSERK1-glutathione S-transferase fusion protein mainly autophosphorylates on threonine residues (K(m) for ATP, 4 x 10(-6) m), and the reaction is Mg(2+) dependent and inhibited by Mn(2+). A K330E substitution in the kinase domain of AtSERK1 abolishes all kinase activity. The active AtSERK1(kin) can phosphorylate inactive AtSERK1(K330E) protein, suggesting an intermolecular mechanism of autophosphorylation. The AtSERK1 kinase protein was modeled using the insulin receptor kinase as a template. On the basis of this model, threonine residues in the AtSERK1 activation loop of catalytic subdomain VIII are potential targets for phosphorylation. AtSERK1 phosphorylation on myelin basic protein and casein showed tyrosine, serine, and threonine as targets, demonstrating that AtSERK1 is a dual specificity kinase. Replacing Thr-468 with either alanine or glutamic acid not only obliterated the ability of the AtSERK1 protein to be phosphorylated but also inhibited phosphorylation on myelin basic protein and casein, suggesting that Thr-468 is essential for AtSERK-mediated signaling.